United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $565.98, for a total value of $5,376,810.00. Following the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,929,547.74. This represents a 19.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Trading Up 0.3%

Shares of UTHR traded up $1.94 during midday trading on Thursday, reaching $565.87. 418,827 shares of the company were exchanged, compared to its average volume of 477,460. The stock has a 50-day moving average price of $562.18 and a 200-day moving average price of $510.32. The company has a market cap of $24.02 billion, a price-to-earnings ratio of 20.89, a P/E/G ratio of 1.83 and a beta of 0.60. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.63 EPS. Equities research analysts anticipate that United Therapeutics Corporation will post 27.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Morgan Stanley set a $516.00 price objective on United Therapeutics in a research note on Thursday, May 7th. Raymond James Financial assumed coverage on United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective on the stock. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday. HC Wainwright boosted their price objective on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Finally, Cantor Fitzgerald boosted their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $619.42.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. AE Wealth Management LLC boosted its position in shares of United Therapeutics by 396.3% during the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after buying an additional 3,424 shares during the period. Great Lakes Advisors LLC boosted its position in shares of United Therapeutics by 194.7% during the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after buying an additional 2,975 shares during the period. Optimize Financial Inc acquired a new position in shares of United Therapeutics during the third quarter worth approximately $444,000. Tobam boosted its position in shares of United Therapeutics by 183.9% during the third quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock worth $3,205,000 after buying an additional 4,953 shares during the period. Finally, Perpetual Ltd acquired a new position in shares of United Therapeutics during the fourth quarter worth approximately $1,059,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.